These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 17392715)

  • 21. [Immunoconjugates, drug-armed antibodies to fight against cancer].
    Haeuw JF; Caussanel V; Beck A
    Med Sci (Paris); 2009 Dec; 25(12):1046-52. PubMed ID: 20035677
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antibody-based therapeutics in oncology.
    Ross J; Gray K; Schenkein D; Greene B; Gray GS; Shulok J; Worland PJ; Celniker A; Rolfe M
    Expert Rev Anticancer Ther; 2003 Feb; 3(1):107-21. PubMed ID: 12597355
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Naptumomab estafenatox: a new immunoconjugate.
    Robinson MK; Alpaugh RK; Borghaei H
    Expert Opin Biol Ther; 2010 Feb; 10(2):273-9. PubMed ID: 20053143
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The next generation of antibody-drug conjugates comes of age.
    Beck A; Haeuw JF; Wurch T; Goetsch L; Bailly C; Corvaïa N
    Discov Med; 2010 Oct; 10(53):329-39. PubMed ID: 21034674
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antibody conjugate therapeutics: challenges and potential.
    Teicher BA; Chari RV
    Clin Cancer Res; 2011 Oct; 17(20):6389-97. PubMed ID: 22003066
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Arming antibodies for cancer therapy.
    Polakis P
    Curr Opin Pharmacol; 2005 Aug; 5(4):382-7. PubMed ID: 15951239
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Monoclonal antibodies in therapy of solid tumors.
    Heimann DM; Weiner LM
    Surg Oncol Clin N Am; 2007 Oct; 16(4):775-92, viii. PubMed ID: 18022544
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Design, synthesis, and in vitro evaluation of dipeptide-based antibody minor groove binder conjugates.
    Jeffrey SC; Torgov MY; Andreyka JB; Boddington L; Cerveny CG; Denny WA; Gordon KA; Gustin D; Haugen J; Kline T; Nguyen MT; Senter PD
    J Med Chem; 2005 Mar; 48(5):1344-58. PubMed ID: 15743178
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antibody-drug conjugates for the treatment of cancer.
    Flygare JA; Pillow TH; Aristoff P
    Chem Biol Drug Des; 2013 Jan; 81(1):113-21. PubMed ID: 23253133
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antibody-drug conjugates in cancer therapy.
    Sievers EL; Senter PD
    Annu Rev Med; 2013; 64():15-29. PubMed ID: 23043493
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Monoclonal antibody drug immunoconjugates for targeted treatment of cancer.
    Trail PA; King HD; Dubowchik GM
    Cancer Immunol Immunother; 2003 May; 52(5):328-37. PubMed ID: 12700948
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of humanized antibodies as cancer therapeutics.
    Qu Z; Griffiths GL; Wegener WA; Chang CH; Govindan SV; Horak ID; Hansen HJ; Goldenberg DM
    Methods; 2005 May; 36(1):84-95. PubMed ID: 15848077
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Human antibodies from transgenic animals.
    Lonberg N
    Nat Biotechnol; 2005 Sep; 23(9):1117-25. PubMed ID: 16151405
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cationization of monoclonal antibodies: another step towards the "magic bullet"?
    Vaisitti T; Deaglio S; Malavasi F
    J Biol Regul Homeost Agents; 2005; 19(3-4):105-12. PubMed ID: 16602624
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Monoclonal antibody therapy for prostate cancer.
    Jakobovits A
    Handb Exp Pharmacol; 2008; (181):237-56. PubMed ID: 18071949
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gpnmb/osteoactivin, an attractive target in cancer immunotherapy.
    Zhou LT; Liu FY; Li Y; Peng YM; Liu YH; Li J
    Neoplasma; 2012; 59(1):1-5. PubMed ID: 22017590
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Guided molecular missiles for tumor-targeting chemotherapy--case studies using the second-generation taxoids as warheads.
    Ojima I
    Acc Chem Res; 2008 Jan; 41(1):108-19. PubMed ID: 17663526
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular, biologic, and pharmacokinetic properties of monoclonal antibodies: impact of these parameters on early clinical development.
    Mascelli MA; Zhou H; Sweet R; Getsy J; Davis HM; Graham M; Abernethy D
    J Clin Pharmacol; 2007 May; 47(5):553-65. PubMed ID: 17379759
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antibody-drug conjugates for cancer therapy: The technological and regulatory challenges of developing drug-biologic hybrids.
    Hamilton GS
    Biologicals; 2015 Sep; 43(5):318-32. PubMed ID: 26115630
    [TBL] [Abstract][Full Text] [Related]  

  • 40. chFRP5-ZZ-PE38, a large IgG-toxin immunoconjugate outperforms the corresponding smaller FRP5(Fv)-ETA immunotoxin in eradicating ErbB2-expressing tumor xenografts.
    Mazor Y; Noy R; Wels WS; Benhar I
    Cancer Lett; 2007 Nov; 257(1):124-35. PubMed ID: 17698286
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.